|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
|
US5208020A
(en)
*
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CN100482281C
(zh)
|
1999-06-25 |
2009-04-29 |
基因技术股份有限公司 |
抗ErbB抗体-类美坦素偶联物在制备药物中的应用
|
|
HK1049787B
(en)
|
1999-10-01 |
2014-07-25 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
EP2335728A1
(de)
|
2001-05-11 |
2011-06-22 |
Ludwig Institute for Cancer Research Ltd. |
Spezifische Bindeproteine und deren Verwendungen
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
|
CA2633171C
(en)
|
2001-06-20 |
2012-11-20 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
|
KR101008758B1
(ko)
|
2001-09-18 |
2011-01-14 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
|
US20110045005A1
(en)
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
WO2005049075A2
(en)
|
2003-11-17 |
2005-06-02 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
MXPA04006554A
(es)
|
2002-01-02 |
2005-03-31 |
Genentech Inc |
Composiciones y metodos para diagnostico y tratamiento de tumor.
|
|
AU2003230874A1
(en)
|
2002-04-16 |
2003-11-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US20090068178A1
(en)
*
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
|
AU2004239301B2
(en)
|
2003-05-09 |
2010-08-19 |
Diadexus, Inc. |
OVR110 antibody compositions and methods of use
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
DK1651162T3
(en)
|
2003-05-20 |
2016-02-01 |
Immunogen Inc |
IMPROVED CYTOTOXIC AGENTS WITH NEW MAYTANSINOIDS
|
|
IN2012DN00313A
(de)
|
2003-06-27 |
2015-05-08 |
Amgen Fremont Inc |
|
|
DK2784084T4
(da)
|
2003-07-08 |
2024-01-08 |
Novartis Pharma Ag |
Antagonist-antistoffer mod IL-17A/F heterologe polypeptider
|
|
JP2007501011A
(ja)
*
|
2003-08-01 |
2007-01-25 |
ジェネンテック・インコーポレーテッド |
制限多様性配列を有する結合型ポリペプチド
|
|
ES2384569T3
(es)
|
2003-12-19 |
2012-07-09 |
Genentech, Inc. |
Fragmentos de anticuerpos monovalentes útiles como agentes terapéuticos
|
|
NZ579482A
(en)
|
2004-06-01 |
2011-02-25 |
Genentech Inc |
Antibody drug conjugates and methods
|
|
KR101254815B1
(ko)
|
2004-07-20 |
2013-09-03 |
제넨테크, 인크. |
안지오포이에틴-유사 4 단백질의 저해제, 배합물, 그의용도
|
|
BRPI0512482A
(pt)
|
2004-07-26 |
2008-03-11 |
Genentech Inc |
método de identificação de uma substáncia inibidora candidata e molécula antagonista
|
|
US20060045877A1
(en)
*
|
2004-08-30 |
2006-03-02 |
Goldmakher Viktor S |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
|
MX337423B
(es)
*
|
2004-09-03 |
2016-03-04 |
Genentech Inc |
Antagonistas anti-beta7 humanizados y usos para los mismos.
|
|
DE602006013275D1
(de)
|
2005-01-07 |
2010-05-12 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
|
JP2008541781A
(ja)
|
2005-06-06 |
2008-11-27 |
ジェネンテック・インコーポレーテッド |
異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
|
|
WO2007094842A2
(en)
*
|
2005-12-02 |
2007-08-23 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
|
EP1922410A2
(de)
|
2005-08-15 |
2008-05-21 |
Genentech, Inc. |
Genunterbrechungen, zusammensetzungen und verfahren in verbindung damit
|
|
US8679490B2
(en)
|
2005-11-07 |
2014-03-25 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
|
AU2006335053A1
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
|
EP3006466B1
(de)
|
2005-12-02 |
2018-08-01 |
Genentech, Inc. |
Zusammensetzungen und verfahren für die behandlung von krankheiten und störungen in zusammenhang mit der zytokinsignalisierung
|
|
WO2007120334A2
(en)
|
2005-12-15 |
2007-10-25 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
|
RU2450020C2
(ru)
|
2006-01-05 |
2012-05-10 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ EphB4 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
KR101617108B1
(ko)
|
2006-01-20 |
2016-04-29 |
제넨테크, 인크. |
항-ｅｐｈｒｉｎｂ２ 항체 및 그의 사용 방법
|
|
EP1988768A2
(de)
|
2006-02-17 |
2008-11-12 |
Genentech, Inc. |
Genunterbrechungen sowie dazugehörige zusammensetzungen und verfahren
|
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
|
EP2007428A2
(de)
|
2006-04-05 |
2008-12-31 |
Genentech, Inc. |
Verfahren zur verwendung von boc/cdo zur modulation der hedgehog-signalisierung
|
|
EP2082645A1
(de)
|
2006-04-19 |
2009-07-29 |
Genentech, Inc. |
Neuartige Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
|
|
PL2032606T3
(pl)
|
2006-05-30 |
2014-04-30 |
Genentech Inc |
Przeciwciała i immunokoniugaty oraz ich zastosowania
|
|
ES2372217T3
(es)
|
2006-09-12 |
2012-01-17 |
Genentech, Inc. |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
|
|
CA2667019C
(en)
|
2006-10-27 |
2016-03-29 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
JP5391073B2
(ja)
|
2006-11-27 |
2014-01-15 |
ディアデクサス インコーポレーテッド |
Ｏｖｒ１１０抗体組成物および使用方法
|
|
MX338185B
(es)
|
2007-01-25 |
2016-04-05 |
Dana Farber Cancer Inst Inc |
Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
|
|
AU2008216495A1
(en)
|
2007-02-09 |
2008-08-21 |
Genentech, Inc. |
Anti-Robo4 antibodies and uses therefor
|
|
US9023356B2
(en)
|
2007-03-15 |
2015-05-05 |
Ludwig Institute For Cancer Research Ltd |
Treatment method using EGFR antibodies and SRC inhibitors and related formulations
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
|
CN101802013B
(zh)
|
2007-07-16 |
2014-07-02 |
健泰科生物技术公司 |
人源化抗cd79b抗体和免疫偶联物及使用方法
|
|
CA3160831A1
(en)
|
2007-07-16 |
2009-01-22 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
JP5532486B2
(ja)
|
2007-08-14 |
2014-06-25 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
|
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
AU2008321016B2
(en)
|
2007-11-12 |
2013-03-28 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
|
HRP20140604T1
(hr)
|
2007-12-26 |
2014-09-12 |
Biotest Ag |
Sredstva koja djeluju na cd138 i njihova upotreba
|
|
AU2008339911B2
(en)
*
|
2007-12-26 |
2014-02-27 |
Biotest Ag |
Immunoconjugates targeting CD138 and uses thereof
|
|
RU2486203C2
(ru)
*
|
2007-12-26 |
2013-06-27 |
Биотест Аг |
Способы улучшения направленного воздействия на cd138-экспрессирующие опухолевые клетки и агенты для их осуществления
|
|
US9011864B2
(en)
*
|
2007-12-26 |
2015-04-21 |
Biotest Ag |
Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
|
|
EP2247617B1
(de)
|
2008-01-18 |
2013-02-27 |
Genentech, Inc. |
Verfahren und zusammensetzungen zum targeting von polyubiquitin
|
|
EP3269737B1
(de)
|
2008-01-31 |
2024-06-19 |
Genentech, Inc. |
Anti-cd79b-antikörper und immunkonjugate sowie verfahren zur verwendung
|
|
EP2257571B1
(de)
|
2008-03-10 |
2015-03-04 |
Theraclone Sciences, Inc. |
Zusammensetzungen und methoden zur therapie und diagnose von cytomegalovirus-infektionen
|
|
NZ621433A
(en)
|
2008-03-18 |
2015-10-30 |
Genentech Inc |
Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
|
CA2905334A1
(en)
|
2008-04-09 |
2009-10-15 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
|
BRPI0908665A2
(pt)
*
|
2008-05-16 |
2020-08-18 |
Genentech Inc |
método para a determinação da eficácia de um antagonista de integrina beta7 para o tratamento de um distúrbio inflamatório gastrointestinal, método de predição da responsividade de um paciente, método para a determinaçao da dosagem de um antagonista de integrina beta7, método para determinaçao do regime terapêutico de um antagonista de integrina beta7, método para predição de prognóstico de uma doença inflamatória intestinal, método de elaboração de um tratamento e método de identificação de uma população de linfócitos
|
|
DK2318832T3
(da)
|
2008-07-15 |
2014-01-20 |
Academia Sinica |
Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
|
|
WO2010039832A1
(en)
|
2008-10-01 |
2010-04-08 |
Genentech, Inc. |
Anti-notch2 antibodies and methods of use
|
|
WO2010080528A1
(en)
|
2008-12-17 |
2010-07-15 |
Genentech, Inc. |
Hepatitis c virus combination therapy
|
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
|
KR20150036824A
(ko)
|
2009-03-20 |
2015-04-07 |
제넨테크, 인크. |
이중특이적 항-ｈｅｒ 항체
|
|
US8410250B2
(en)
*
|
2009-03-25 |
2013-04-02 |
Genentech, Inc. |
Anti-FGFR3 antibodies and methods using same
|
|
WO2010120561A1
(en)
|
2009-04-01 |
2010-10-21 |
Genentech, Inc. |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
|
SG175004A1
(en)
|
2009-04-02 |
2011-11-28 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
|
CN102459340A
(zh)
*
|
2009-04-23 |
2012-05-16 |
特罗科隆科学有限公司 |
粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
|
|
EP2432803A2
(de)
|
2009-05-20 |
2012-03-28 |
Theraclone Sciences, Inc. |
Zusammensetzungen und verfahren zur therapie und diagnose von grippe
|
|
CN102802661B
(zh)
|
2009-06-22 |
2016-01-13 |
米迪缪尼有限公司 |
用于位点特异性偶联的工程改造的Fc区
|
|
CA2769308A1
(en)
|
2009-07-31 |
2011-02-03 |
Genentech, Inc. |
Inhibition of tumor metastasis using bv8- or g-csf-antagonists
|
|
JP5887270B2
(ja)
|
2009-09-02 |
2016-03-16 |
ジェネンテック， インコーポレイテッド |
突然変異体ｓｍｏｏｔｈｅｎｅｄおよびその使用方法
|
|
NZ701769A
(en)
|
2009-09-16 |
2016-06-24 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
RU2012120693A
(ru)
*
|
2009-10-19 |
2013-12-20 |
Дженентек, Инк. |
Модуляторы активатора фактора роста гепатоцитов
|
|
CN102711826B
(zh)
|
2009-10-22 |
2017-03-29 |
霍夫曼-拉罗奇有限公司 |
用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
|
|
CN102648211B
(zh)
|
2009-10-22 |
2015-04-01 |
霍夫曼-拉罗奇有限公司 |
抗hepsin抗体及其使用方法
|
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
|
ES2636971T3
(es)
|
2009-11-05 |
2017-10-10 |
F. Hoffmann-La Roche Ag |
Procedimientos y composición para la secreción de polipéptidos heterógenos
|
|
RU2015132142A
(ru)
|
2009-11-30 |
2015-12-20 |
Дженентек, Инк. |
Композиции и способы для диагностики и лечения опухоли
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
EP2509626B1
(de)
|
2009-12-11 |
2016-02-10 |
F.Hoffmann-La Roche Ag |
Anti-vegf-c-antikörper und verfahren zu ihrer verwendung
|
|
ES2585350T3
(es)
|
2009-12-23 |
2016-10-05 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti Bv8 y usos de los mismos
|
|
WO2011082187A1
(en)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Methods for modulating a pdgf-aa mediated biological response
|
|
AU2011221226A1
(en)
|
2010-02-23 |
2012-08-16 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
CN102946906B
(zh)
|
2010-04-23 |
2015-07-15 |
弗·哈夫曼-拉罗切有限公司 |
生产异源多聚体蛋白质
|
|
PE20130460A1
(es)
|
2010-05-03 |
2013-04-26 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
|
NZ602840A
(en)
|
2010-06-03 |
2014-11-28 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
|
CA2807664A1
(en)
|
2010-08-12 |
2012-02-16 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
|
WO2012025530A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
|
PL3556396T3
(pl)
|
2010-08-31 |
2022-09-12 |
Theraclone Sciences, Inc. |
Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
|
|
RU2013115927A
(ru)
|
2010-09-10 |
2014-10-20 |
Апексиджен, Инк. |
АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
|
|
ES2588981T3
(es)
|
2010-10-05 |
2016-11-08 |
Genentech, Inc. |
Smoothened mutante y métodos de uso de la misma
|
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
|
CA2825064C
(en)
|
2011-02-04 |
2022-08-30 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
KR20140012098A
(ko)
|
2011-02-14 |
2014-01-29 |
테라클론 사이언시스, 아이엔씨. |
인플루엔자의 치료 및 진단을 위한 조성물 및 방법
|
|
US8753634B2
(en)
|
2011-03-03 |
2014-06-17 |
Apexigen, Inc. |
Anti-IL-6 receptor antibodies and methods of use
|
|
JP2014509591A
(ja)
|
2011-03-15 |
2014-04-21 |
セラクローン サイエンシーズ， インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
|
MX339239B
(es)
|
2011-04-29 |
2016-05-18 |
Apexigen Inc |
Anticuerpos anti-cd40 y metodos de uso.
|
|
CN103648523A
(zh)
|
2011-05-09 |
2014-03-19 |
弗吉尼亚大学专利基金会 |
用于治疗癌症的组合物和方法
|
|
CA2833820C
(en)
|
2011-05-27 |
2019-10-29 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
RU2014109985A
(ru)
|
2011-08-17 |
2015-09-27 |
Дженентек, Инк. |
Ингибирование ангиогенеза в рефрактерных опухолях
|
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
|
CA2849318C
(en)
|
2011-09-22 |
2019-11-12 |
Amgen Inc. |
Cd27l antigen binding proteins
|
|
EA201490879A1
(ru)
|
2011-10-28 |
2014-08-29 |
Дженентек, Инк. |
Терапевтические комбинации и способы лечения меланомы
|
|
EP2785742B1
(de)
|
2011-11-02 |
2020-01-08 |
Apexigen, Inc. |
Anti-kdr-antikörper und verwendungsverfahren dafür
|
|
SG11201402365RA
(en)
|
2011-11-16 |
2014-06-27 |
Amgen Inc |
Methods of treating epidermal growth factor deletion mutant viii related disorders
|
|
RU2632108C2
(ru)
|
2011-12-08 |
2017-10-02 |
Биотест Аг |
Применения иммуноконъюгатов, мишенью которых является cd138
|
|
WO2013093809A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
US20140050720A1
(en)
|
2012-01-09 |
2014-02-20 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
|
EP2802601B1
(de)
|
2012-01-09 |
2019-11-13 |
The Scripps Research Institute |
Humanisierte antikörper mit ultralangem cdr3s
|
|
RU2644341C2
(ru)
|
2012-02-10 |
2018-02-08 |
Дженентек, Инк. |
Одноцепочечные антитела и другие гетеромультимеры
|
|
CN104379602B
(zh)
|
2012-03-08 |
2017-05-03 |
哈洛齐梅公司 |
具有条件活性的抗表皮生长因子受体抗体及其使用方法
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
AU2013256596A1
(en)
|
2012-05-01 |
2014-10-09 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
|
JO3623B1
(ar)
|
2012-05-18 |
2020-08-27 |
Amgen Inc |
البروتينات المرتبطة بمولد المستضاد st2
|
|
MX354862B
(es)
|
2012-06-27 |
2018-03-23 |
Hoffmann La Roche |
Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
|
|
EP2867254B1
(de)
|
2012-06-27 |
2017-10-25 |
F. Hoffmann-La Roche AG |
Verfahren zum herstellen von antikörper-fc-region-konjugaten mit mindestens einer bindungsstelle, die spezifisch an ein target bindet, und verwendungen davon
|
|
AU2013306098A1
(en)
|
2012-08-18 |
2015-02-12 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
|
NZ739573A
(en)
|
2012-09-26 |
2019-11-29 |
Immunogen Inc |
Improved methods for the acylation of maytansinol
|
|
AU2013337903B2
(en)
|
2012-10-30 |
2018-08-16 |
Apexigen, Inc. |
Anti-CD40 antibodies and methods of use
|
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Ｂｃｍａ抗原結合蛋白質
|
|
CN103254213B
(zh)
*
|
2012-12-21 |
2015-02-25 |
百奥泰生物科技(广州)有限公司 |
类美登素酯的制备方法及用于所述方法的组合物
|
|
US9920121B2
(en)
|
2013-01-25 |
2018-03-20 |
Amgen Inc. |
Antibodies targeting CDH19 for melanoma
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
US10150813B2
(en)
|
2013-03-14 |
2018-12-11 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
CN105007950B
(zh)
|
2013-03-15 |
2019-01-15 |
诺华股份有限公司 |
抗体药物缀合物
|
|
NZ753995A
(en)
|
2013-05-30 |
2022-07-01 |
Kiniksa Pharmaceuticals Ltd |
Oncostatin m receptor antigen binding proteins
|
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
|
CN111518199A
(zh)
|
2013-07-18 |
2020-08-11 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
|
EP3022224A2
(de)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antikörper mit ultralangen komplementaritätsbestimmenden regionen
|
|
EP3747465A1
(de)
|
2013-07-31 |
2020-12-09 |
BioNTech AG |
Diagnose und therapie von krebs mit krebsstammzellen
|
|
EP3041484B1
(de)
|
2013-09-06 |
2021-03-03 |
Academia Sinica |
Humane inkt-zell-aktivierung mittels glykolipiden mit veränderten glycosylgruppen
|
|
JP6282745B2
(ja)
|
2013-09-12 |
2018-02-21 |
ハロザイム インコーポレイテッド |
修飾抗上皮成長因子受容体抗体およびその使用法
|
|
BR112016004450A2
(pt)
|
2013-09-17 |
2017-10-17 |
Genentech Inc |
métodos para tratar uma doença, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir desenvolvimento da reincidência e/ou resistência de uma doença, para aumentar a sensibilidade a um inibidor, para estender o período de sensibilidade a um inibidor e para estender a duração de resposta a um inibidor
|
|
ES2764833T3
(es)
|
2013-10-11 |
2020-06-04 |
The United States Of America Represented By The Sec Dep Of Health And Human Services |
Anticuerpos contra TEM8 y su uso
|
|
US20160280798A1
(en)
|
2013-11-06 |
2016-09-29 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Service |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
|
EA201691214A1
(ru)
|
2013-12-13 |
2016-12-30 |
Дженентек, Инк. |
Антитела к cd33 и иммуноконъюгаты
|
|
KR20170042495A
(ko)
|
2013-12-16 |
2017-04-19 |
제넨테크, 인크. |
펩티드모방체 화합물 및 그의 항체-약물 접합체
|
|
US9982041B2
(en)
|
2014-01-16 |
2018-05-29 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
JP2017505305A
(ja)
|
2014-01-24 |
2017-02-16 |
ジェネンテック， インコーポレイテッド |
抗ｓｔｅａｐ１抗体及びイムノコンジュゲートを使用する方法
|
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
WO2015148915A1
(en)
|
2014-03-27 |
2015-10-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
|
MX2016012830A
(es)
|
2014-04-11 |
2017-01-05 |
Medimmune Llc |
Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
|
|
PL3140392T3
(pl)
|
2014-05-06 |
2023-11-27 |
F. Hoffmann-La Roche Ag |
Produkcja białek heteromultimerycznych z wykorzystaniem komórek ssaków
|
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック， インコーポレイテッド |
抗ｇｐｃ３抗体及びイムノコンジュゲート
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
US10005847B2
(en)
|
2014-05-27 |
2018-06-26 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
|
KR102576850B1
(ko)
|
2014-05-27 |
2023-09-11 |
아카데미아 시니카 |
박테로이드 기원의 푸코시다제 및 이의 사용 방법
|
|
KR20170003720A
(ko)
|
2014-05-27 |
2017-01-09 |
아카데미아 시니카 |
항-ｃｄ20 글리코항체 및 이의 용도
|
|
CN106714829A
(zh)
|
2014-05-28 |
2017-05-24 |
中央研究院 |
抗TNF‑α醣抗体及其用途
|
|
US9982045B2
(en)
|
2014-08-12 |
2018-05-29 |
Novartis Ag |
Anti-CDH6 antibody drug conjugates
|
|
DK4074735T3
(da)
|
2014-08-28 |
2025-07-14 |
Bioatla Inc |
Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
|
|
WO2016040369A2
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
|
KR20170066421A
(ko)
|
2014-09-12 |
2017-06-14 |
제넨테크, 인크. |
항-cll-1 항체 및 면역접합체
|
|
WO2016040724A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
WO2016040723A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-her2 antibodies and immunoconjugates
|
|
BR112017023576A2
(pt)
|
2014-09-23 |
2023-10-03 |
Genentech Inc |
Método para tratar uma disfunção proliferativa de células b
|
|
ES2969960T3
(es)
|
2014-10-01 |
2024-05-23 |
Medimmune Llc |
Método para conjugar un polipéptido
|
|
MX2017003478A
(es)
|
2014-11-05 |
2018-02-01 |
Genentech Inc |
Anticuerpos anti-fgfr2/3 y metodos para su uso.
|
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性抗体
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
JP6779887B2
(ja)
|
2015-01-24 |
2020-11-04 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
新規なグリカンコンジュゲートおよびその使用方法
|
|
TWI710571B
(zh)
|
2015-01-24 |
2020-11-21 |
中央研究院 |
腫瘤標記及其使用方法
|
|
CN107636170A
(zh)
|
2015-02-04 |
2018-01-26 |
健泰科生物技术公司 |
突变型Smoothened及其使用方法
|
|
WO2016145536A1
(en)
|
2015-03-18 |
2016-09-22 |
Immunobiochem Corporation |
Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
|
|
WO2016165762A1
(en)
|
2015-04-15 |
2016-10-20 |
Ganymed Pharmaceuticals Ag |
Drug conjugates comprising antibodies against claudin 18.2
|
|
EP3286227A2
(de)
|
2015-04-24 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Multispezifische antigenbindende proteine
|
|
CA2989347A1
(en)
|
2015-06-12 |
2016-12-15 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered t-cells
|
|
WO2016203432A1
(en)
|
2015-06-17 |
2016-12-22 |
Novartis Ag |
Antibody drug conjugates
|
|
EP4477269A3
(de)
|
2015-09-20 |
2025-03-19 |
The United States of America, as Represented By the Secretary, Department of Health and Human Services |
Für fibroblastenwachstumsfaktor-rezeptor 4 (fgfr4) spezifische monoklonale antikörper und verfahren zu deren verwendung
|
|
CN114181960B
(zh)
|
2015-10-09 |
2024-08-23 |
美天施生物科技有限公司 |
嵌合抗原受体和使用方法
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
AU2017212484C1
(en)
|
2016-01-27 |
2020-11-05 |
Medimmune, Llc |
Methods for preparing antibodies with a defined glycosylation pattern
|
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス，インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
|
AU2017231749A1
(en)
|
2016-03-08 |
2018-09-20 |
Academia Sinica |
Methods for modular synthesis of N-glycans and arrays thereof
|
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
|
CN109563164A
(zh)
|
2016-04-15 |
2019-04-02 |
生物蛋白有限公司 |
抗axl抗体、抗体片段和它们的免疫缀合物以及其用途
|
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
|
SMT202200432T1
(it)
|
2016-05-13 |
2022-11-18 |
Bioatla Inc |
Anticorpi, frammenti anticorpali anti-ror2, loro immunoconiugati e loro usi
|
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
|
WO2018026533A1
(en)
|
2016-08-02 |
2018-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
|
|
CN109963868B
(zh)
|
2016-08-22 |
2023-11-14 |
醣基生医股份有限公司 |
抗体、结合片段及使用方法
|
|
US11453712B2
(en)
|
2016-09-02 |
2022-09-27 |
Lentigen Technology Inc. |
Compositions and methods for treating cancer with DuoCARs
|
|
US11697680B2
(en)
|
2016-11-21 |
2023-07-11 |
Cureab Gmbh |
Anti-GP73 antibodies and immunoconjugates
|
|
US11236171B2
(en)
|
2016-12-21 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
|
CA3096798A1
(en)
|
2017-01-09 |
2018-07-12 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-mesothelin immunotherapy
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
CN112695050B
(zh)
|
2017-03-24 |
2025-08-08 |
莱蒂恩技术公司 |
用于用抗cd33免疫疗法治疗癌症的组合物和方法
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
AU2018268970B2
(en)
|
2017-05-19 |
2024-12-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
|
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
|
WO2019006280A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
|
|
CA3071624A1
(en)
|
2017-07-31 |
2019-02-07 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
|
|
EP3681903B1
(de)
|
2017-09-15 |
2023-07-19 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd19-immuntherapie
|
|
CN111163809B
(zh)
|
2017-09-19 |
2024-07-02 |
保罗·谢勒学院 |
转谷氨酰胺酶缀合方法和接头
|
|
EP3697426B1
(de)
|
2017-10-16 |
2023-07-26 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd22-immuntherapie
|
|
AU2018354189A1
(en)
|
2017-10-24 |
2020-04-23 |
Crispr Therapeutics Ag |
Compositions and methods for the depletion of CD117+ cells
|
|
CN111741757B
(zh)
|
2017-11-03 |
2023-12-19 |
莱蒂恩技术公司 |
用于用抗ror1免疫治疗来治疗癌症的组合物和方法
|
|
MX2020004910A
(es)
|
2017-11-29 |
2020-10-05 |
Magenta Therapeutics Inc |
Composiciones y métodos para el agotamiento de células cd5 +.
|
|
CN111954677A
(zh)
|
2017-12-20 |
2020-11-17 |
莱蒂恩技术公司 |
用于用免疫治疗来治疗hiv/aids的组合物和方法
|
|
AU2019301675B2
(en)
|
2018-07-12 |
2025-09-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Affinity matured CD22-specific monoclonal antibody and uses thereof
|
|
AU2019311077B2
(en)
|
2018-07-23 |
2025-05-29 |
Heidelberg Pharma Research Gmbh |
Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy
|
|
CN112585163B
(zh)
|
2018-08-08 |
2025-03-25 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向磷脂酰肌醇蛋白聚糖-2的高亲和力单克隆抗体及其用途
|
|
CN113260630B
(zh)
|
2018-09-20 |
2024-05-24 |
莱蒂恩技术公司 |
用于用抗cd123免疫治疗来治疗癌症的组合物和方法
|
|
CN118581122A
(zh)
|
2018-09-26 |
2024-09-03 |
莱蒂恩技术公司 |
用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
|
|
CA3121244A1
(en)
|
2018-11-30 |
2020-06-04 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd38 immunotherapy
|
|
AU2018451747A1
(en)
|
2018-12-06 |
2021-06-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
|
|
CA3125484A1
(en)
|
2019-01-08 |
2020-07-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cross-species single domain antibodies targeting mesothelin for treating solid tumors
|
|
CN113784987B
(zh)
|
2019-01-22 |
2024-09-13 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向磷脂酰肌醇蛋白聚糖-1的高亲和力单克隆抗体和使用方法
|
|
EP3934668A1
(de)
|
2019-03-06 |
2022-01-12 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit selbstansteuernden chimären antigen-rezeptoren
|
|
CN113613679A
(zh)
|
2019-03-19 |
2021-11-05 |
保罗·谢勒学院 |
基于甘氨酸的接头的转谷氨酰胺酶缀合方法
|
|
WO2020232169A1
(en)
|
2019-05-14 |
2020-11-19 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma
|
|
US11052112B2
(en)
|
2019-05-30 |
2021-07-06 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-BCMA immunotherapy
|
|
EP3994173A1
(de)
|
2019-07-02 |
2022-05-11 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Monoklonale egfrviii-bindende antikörper und ihre verwendung
|
|
JPWO2021010326A1
(de)
|
2019-07-12 |
2021-01-21 |
|
|
|
CN114945386A
(zh)
|
2019-10-18 |
2022-08-26 |
基因泰克公司 |
使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
|
|
CA3156761A1
(en)
|
2019-10-22 |
2021-04-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors
|
|
WO2021118968A1
(en)
|
2019-12-12 |
2021-06-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-drug conjugates specific for cd276 and uses thereof
|
|
CN115916822A
(zh)
|
2020-04-24 |
2023-04-04 |
基因泰克公司 |
使用抗CD79b免疫缀合物的方法
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
CA3171101A1
(en)
|
2020-06-22 |
2021-12-30 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
|
|
JP2023542910A
(ja)
|
2020-09-18 |
2023-10-12 |
アラリス バイオテック アーゲー |
アミノ酸に基づくリンカーを使用したトランスグルタミナーゼコンジュゲーション方法
|
|
EP4232095A1
(de)
|
2020-10-25 |
2023-08-30 |
Araris Biotech AG |
Mittel und verfahren zur herstellung von antikörper-linker-konjugaten
|
|
US20230391852A1
(en)
|
2020-10-26 |
2023-12-07 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
|
CA3171093A1
(en)
|
2020-11-05 |
2022-05-12 |
Dina SCHNEIDER |
Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
|
|
US20240218055A1
(en)
|
2021-04-29 |
2024-07-04 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
|
WO2022241446A1
(en)
|
2021-05-12 |
2022-11-17 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
CN117396513A
(zh)
|
2021-05-28 |
2024-01-12 |
葛兰素史密斯克莱知识产权发展有限公司 |
治疗癌症的联合疗法
|
|
US20240270851A1
(en)
|
2021-06-09 |
2024-08-15 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
|
US11807685B2
(en)
|
2021-08-05 |
2023-11-07 |
The Uab Research Foundation |
Anti-CD47 antibody and uses thereof
|
|
US20240336697A1
(en)
|
2021-08-07 |
2024-10-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
CN118159294A
(zh)
|
2021-10-05 |
2024-06-07 |
葛兰素史密斯克莱知识产权发展有限公司 |
用于治疗癌症的联合疗法
|
|
CN118159298A
(zh)
|
2021-10-25 |
2024-06-07 |
阿拉里斯生物技术股份公司 |
生产抗体-接头偶联物的方法
|
|
AU2023223556A1
(en)
|
2022-02-22 |
2024-09-12 |
Araris Biotech Ag |
Peptide linkers comprising two or more payloads
|
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
|
CN119923410A
(zh)
|
2022-07-28 |
2025-05-02 |
莱蒂恩技术公司 |
用于治疗实体瘤的嵌合抗原受体治疗
|
|
CA3265857A1
(en)
|
2022-08-26 |
2024-02-29 |
Lentigen Technology, Inc. |
COMPOSITIONS AND METHODS OF CANCER TREATMENT BY ALL-HUMAN ANTI-CD20/CD19 IMMUNOTHERAPY
|
|
WO2024218345A1
(en)
|
2023-04-21 |
2024-10-24 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies
|
|
AU2024283865A1
(en)
|
2023-06-08 |
2025-11-27 |
Genentech, Inc. |
Macrophage signatures for diagnostic and therapeutic methods for lymphoma
|
|
WO2025014896A1
(en)
|
2023-07-07 |
2025-01-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Humanized 40h3 antibody
|
|
WO2025019228A1
(en)
|
2023-07-20 |
2025-01-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
|
|
WO2025082990A1
(en)
|
2023-10-15 |
2025-04-24 |
Araris Biotech Ag |
Antibody-drug conjugates using two different types of topoisomerase i inhibitors
|
|
WO2025171238A1
(en)
|
2024-02-07 |
2025-08-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof
|
|
WO2026006682A1
(en)
|
2024-06-27 |
2026-01-02 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating cancer with il7fc armored car-t cells
|
|
US20260014265A1
(en)
|
2024-07-10 |
2026-01-15 |
Araris Biotech Ag |
TRIPLE-PAYLOAD ANTIBODY-DRUG CONJUGATES (ADCs)
|